Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taha Merghoub

Showing results (141-150 of 216) with videos related to

Pageof 22
Sort By:
Nature Communications|August 1, 2020
Escape from nonsense-mediated decay associates with anti-tumor immunogenicityKevin Litchfield, James L Reading, Emilia L Lim, et al.
Cell Research|July 15, 2025
Human myelocyte and metamyelocyte-stage neutrophils suppress tumor immunity and promote cancer progressionWei Liu, Tao Shi, Chun Lu, et al.
Journal for Immunotherapy of Cancer|June 3, 2026
Expert opinion on burning questions in cancer myeloid cell biologyJennifer L Guerriero, Miriam Merad, Florent Ginhoux, et al.
The Journal of Clinical Investigation|July 23, 2019
In situ vaccination with defined factors overcomes T cell exhaustion in distant tumorsDanny N Khalil, Nathan Suek, Luis Felipe Campesato, et al.
Plos One|December 19, 2013
Enhanced responses to tumor immunization following total body irradiation are time-dependentAdi Diab, Robert R Jenq, Gabrielle A Rizzuto, et al.
The New England Journal of Medicine|November 20, 2014
Genetic basis for clinical response to CTLA-4 blockade in melanomaAlexandra Snyder, Vladimir Makarov, Taha Merghoub, et al.
Plos Medicine|May 30, 2017
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysisAlexandra Snyder, Tavi Nathanson, Samuel A Funt, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trialDmitriy Zamarin, Sven Walderich, Aliya Holland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 10, 2021
Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung CancerJia Luo, Victoria L Martucci, Zoe Quandt, et al.
The Journal of Biological Chemistry|May 5, 2017
HMG-CoA synthase 1 is a synthetic lethal partner of BRAF<sup>V600E</sup> in human cancersLiang Zhao, Jun Fan, Siyuan Xia, et al.
Pageof 22

Showing results (141-150 of 216) with videos related to

Sort By:
Pageof 22
Nature Communications|August 1, 2020
Escape from nonsense-mediated decay associates with anti-tumor immunogenicityKevin Litchfield, James L Reading, Emilia L Lim, et al.
Cell Research|July 15, 2025
Human myelocyte and metamyelocyte-stage neutrophils suppress tumor immunity and promote cancer progressionWei Liu, Tao Shi, Chun Lu, et al.
Journal for Immunotherapy of Cancer|June 3, 2026
Expert opinion on burning questions in cancer myeloid cell biologyJennifer L Guerriero, Miriam Merad, Florent Ginhoux, et al.
The Journal of Clinical Investigation|July 23, 2019
In situ vaccination with defined factors overcomes T cell exhaustion in distant tumorsDanny N Khalil, Nathan Suek, Luis Felipe Campesato, et al.
Plos One|December 19, 2013
Enhanced responses to tumor immunization following total body irradiation are time-dependentAdi Diab, Robert R Jenq, Gabrielle A Rizzuto, et al.
The New England Journal of Medicine|November 20, 2014
Genetic basis for clinical response to CTLA-4 blockade in melanomaAlexandra Snyder, Vladimir Makarov, Taha Merghoub, et al.
Plos Medicine|May 30, 2017
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysisAlexandra Snyder, Tavi Nathanson, Samuel A Funt, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trialDmitriy Zamarin, Sven Walderich, Aliya Holland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 10, 2021
Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung CancerJia Luo, Victoria L Martucci, Zoe Quandt, et al.
The Journal of Biological Chemistry|May 5, 2017
HMG-CoA synthase 1 is a synthetic lethal partner of BRAF<sup>V600E</sup> in human cancersLiang Zhao, Jun Fan, Siyuan Xia, et al.
Pageof 22